TTOO - A Roadmap To T2 Biosystems Story

• The company has ramped up its revenues and instrument placements and also initiated T2Biothreat and T2Resistance Panel clinical trials.
• The war in Ukraine may accelerate updates regarding the T2Biothreat panel.
• Their international presence is increasing more rapidly than their U.S. presence, considering that their main focus is in the domestic market.
• The straightforward denial of a possible reverse stock split by the management, in combination with the rest of the developments mentioned, leads me to the conclusion that the worst has passed for the company.

For further details see: